In line with this seminal work, our results provide evidence indicating that higher levels of Aβ and phosphorylated tau are associated with greater deterioration of the CP integrity, including in individuals without cognitive impairment consistent with evidence that biomarker and brain changes occur years before clinical symptoms. The gene discussed is MAPT; the disease is Cognitive impairment.